Compounds > spironolactone
Page last updated: 2024-11-07

spironolactone and Albuminuria

spironolactone has been researched along with Albuminuria in 65 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

ExcerptRelevanceReference
"The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in subjects with diabetic kidney disease, albeit with a large variability between individuals."9.34Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. ( Hankemeier, T; Heerspink, HJL; Jacobsen, IA; Mehdi, UF; Mulder, S; Oxlund, C; Pena, MJ; Perco, P; Toto, R, 2020)
"The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in patients with diabetes."9.27Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. ( Heerspink, HJL; Jacobsen, IA; Lindhardt, M; Mischak, H; Oxlund, C; Persson, F; Rossing, P; Zürbig, P, 2018)
" Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial."9.24Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017)
"This study investigated the effects and safety of eplerenone or thiazide diuretics in patients with hypertension and albuminuria (pretreatment urinary albumin/creatinine ratio ≥10 mg/gCr) treated with an angiotensin II receptor blocker."9.24Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension. ( Dohi, K; Fujimoto, N; Ichikawa, T; Isaka, N; Ito, M; Kitamura, T; Koyabu, S; Makino, K; Nakamura, M; Nishikawa, M; Ogura, T; Okamoto, S; Okubo, S; Sawai, T; Tamaru, S; Yamada, T, 2017)
"High-dose spironolactone added to standard ADHF therapy is likely to induce a more pronounced albuminuria decrease and a significant reduction in the proportion of micro and macroalbuminuria."9.19The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. ( Almeida, S; Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Santos, M, 2014)
"Addition of low-dose eplerenone to renin-angiotensin system inhibitors might have renoprotective effects through reduction of albuminuria in hypertensive patients with non-diabetic chronic kidney disease, without serious safety concerns."9.19Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. ( Ando, K; Arakawa, Y; Fujita, T; Kaname, S; Ohtsu, H; Uchida, S, 2014)
"The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days."9.17Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013)
" We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria."9.16Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. ( Frandsen, E; Hess, G; Nielsen, SE; Parving, HH; Persson, F; Rossing, P; Shjoedt, KJ; Sugaya, T; Zdunek, D, 2012)
"To investigate whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors further decreases albuminuria in patients with type 2 diabetes mellitus (DM)."9.13Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. ( Davidson, MB; Hamrahian, AH; Siraj, ES; Stevens, M; Wong, A, 2008)
"Previous studies have shown that the selective aldosterone blocker eplerenone, in doses of up to 200 mg/d, reduces albuminuria in patients with type 2 diabetes."9.12Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. ( Beckerman, B; Epstein, M; Krause, S; Lewin, A; Mukherjee, R; Patni, R; Weinberger, M; Williams, GH, 2006)
"At the doses tested, spironolactone was superior to cilazapril in reducing albuminuria."9.11The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. ( Amit, M; Berla, M; Kedar, Y; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 2004)
"This study compared the efficacy and tolerability of eplerenone and enalapril in 499 patients with stage 1 or 2 hypertension who were randomized to receive eplerenone or enalapril for 6 months in a 3-step titration-to-effect study."9.11Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. ( Burgess, E; Kipnes, MS; Kolloch, RE; Krause, SL; Niegowska, J; Patrick, JL; Roniker, B; Ruilope, LM; Williams, GH, 2004)
"Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure."9.10Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003)
" We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744)."7.88Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. ( Anand, I; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Selvaraj, S; Shah, SJ; Solomon, SD; Sweitzer, NK, 2018)
" It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension."7.76Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010)
"Amiloride (5 mg/d) was added to previous triple antihypertensive treatment (including a diuretic and an inhibitor of the renin-angiotensin-aldosterone system) and increased to 10 mg if BP control was not achieved at 4 weeks."6.79Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension. ( Buhl, KB; Gram, J; Hansen, MR; Henriksen, JE; Jacobsen, IA; Jensen, BL; Oxlund, CS; Schousboe, K; Tarnow, L, 2014)
"Aldosterone breakthrough has the potential to eliminate the organ-protective effects of RA system inhibitors."6.78Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist. ( Fukuda, S; Sato, A, 2013)
"Primary aldosteronism (PA) has deleterious effects on kidney function independent of blood pressure levels."6.78Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. ( Allolio, B; Beuschlein, F; Diederich, S; Endres, S; Fischer, E; Fourkiotis, V; Lang, K; Quinkler, M; Reincke, M; Rump, LC; Vonend, O; Willenberg, HS, 2013)
"Twenty Caucasian patients with diabetic nephropathy and nephrotic range albuminuria (>2500 mg/24 h) despite recommended antihypertensive treatment completed this double-masked, randomized crossover trial."6.72Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006)
"Low-dose spironolactone administration reduced albuminuria without causing hyperkalemia."5.69Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes. ( Hiwatashi, D; Kawata, I; Koinuma, M; Komatsu, M; Miyamoto, T; Oiwa, A; Takeda, T; Yamazaki, M, 2023)
"Patients with primary aldosteronism (PA) have a high prevalence of microalbuminuria (MAU), which leads to more severe systemic vascular damage."5.62Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism. ( Hu, J; Li, N; Luo, Q; Wang, G; Wang, M; Wang, X; Zhang, D; Zhang, W, 2021)
"The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in subjects with diabetic kidney disease, albeit with a large variability between individuals."5.34Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. ( Hankemeier, T; Heerspink, HJL; Jacobsen, IA; Mehdi, UF; Mulder, S; Oxlund, C; Pena, MJ; Perco, P; Toto, R, 2020)
"The mineralocorticoid receptor antagonist spironolactone significantly reduces albuminuria in patients with diabetes."5.27Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. ( Heerspink, HJL; Jacobsen, IA; Lindhardt, M; Mischak, H; Oxlund, C; Persson, F; Rossing, P; Zürbig, P, 2018)
"This study investigated the effects and safety of eplerenone or thiazide diuretics in patients with hypertension and albuminuria (pretreatment urinary albumin/creatinine ratio ≥10 mg/gCr) treated with an angiotensin II receptor blocker."5.24Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension. ( Dohi, K; Fujimoto, N; Ichikawa, T; Isaka, N; Ito, M; Kitamura, T; Koyabu, S; Makino, K; Nakamura, M; Nishikawa, M; Ogura, T; Okamoto, S; Okubo, S; Sawai, T; Tamaru, S; Yamada, T, 2017)
" Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial."5.24Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin. ( Bistrup, C; Hansen, MR; Hansen, PB; Hinrichs, GR; Jacobsen, IA; Jensen, BL; Kurt, B; Oxlund, C; Schwarzensteiner, I; Stæhr, M; Svenningsen, P; Thuesen, AD; Toft, A, 2017)
"Spironolactone reduced albuminuria along with conventional RAS inhibitors in patients with diabetic nephropathy."5.20Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. ( Ando, M; Araki, H; Goto, M; Imai, E; Kanasaki, K; Kato, S; Kobori, H; Koya, D; Makino, H; Maruyama, S; Matsuo, S; Nishiyama, A; Ogawa, D; Oiso, Y; Uzu, T; Wada, J, 2015)
"High-dose spironolactone added to standard ADHF therapy is likely to induce a more pronounced albuminuria decrease and a significant reduction in the proportion of micro and macroalbuminuria."5.19The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. ( Almeida, S; Bettencourt, P; Carvalho, H; Ferreira, JP; Marques, I; Santos, M, 2014)
"Addition of low-dose eplerenone to renin-angiotensin system inhibitors might have renoprotective effects through reduction of albuminuria in hypertensive patients with non-diabetic chronic kidney disease, without serious safety concerns."5.19Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. ( Ando, K; Arakawa, Y; Fujita, T; Kaname, S; Ohtsu, H; Uchida, S, 2014)
"The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days."5.17Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. ( Nielsen, SE; Parving, HH; Persson, F; Rossing, K; Rossing, P; Schalkwijk, CG; Schjoedt, KJ; Stehouwer, CD, 2013)
" The aim was to compare the effects on albuminuria of the therapy with either: (i) telmisartan 80 mg and aliskiren 300 mg, (ii) telmisartan 80 mg and eplerenone 50 mg, (iii) telmisartan 160 mg as monotherapy."5.16The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?. ( Bednarski, R; Donderski, R; Heleniak, Z; Lizakowski, S; Manitius, J; Przybylska, M; Renke, M; Rutkowski, B; Rutkowski, P; Sulikowska, B; Tylicki, L, 2012)
" We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria."5.16Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. ( Frandsen, E; Hess, G; Nielsen, SE; Parving, HH; Persson, F; Rossing, P; Shjoedt, KJ; Sugaya, T; Zdunek, D, 2012)
"Spironolactone did not change the overall ability to autoregulate GFR in 16 hypertensive type 1 diabetic patients with normoalbuminuria."5.14Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial. ( Boomsma, F; Christensen, PK; Jorsal, A; Parving, HH; Rossing, P; Schjoedt, KJ, 2009)
" We conducted a double-blind, placebo-controlled trial in 81 patients with diabetes, hypertension, and albuminuria (urine albumin-to-creatinine ratio > or =300 mg/g) who all received lisinopril (80 mg once daily)."5.14Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. ( Adams-Huet, B; Mehdi, UF; Raskin, P; Toto, RD; Vega, GL, 2009)
"To investigate whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors further decreases albuminuria in patients with type 2 diabetes mellitus (DM)."5.13Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. ( Davidson, MB; Hamrahian, AH; Siraj, ES; Stevens, M; Wong, A, 2008)
" We sought to evaluate the effects of a three-month treatment with 25 mg spironolactone, an aldosterone receptor antagonist, on nephron function in 20 type II diabetic patients with persistent microalbuminuria, despite at least six months' use of an ACEi or ARB (combination group), and in eleven type II diabetic patients with persistent microalbuminuria who have never used an ACEi or an ARB (spironolactone group)."5.13The effects of spironolactone on nephron function in patients with diabetic nephropathy. ( Demirkan, B; Sut, N; Tugrul, A; Ustundag, A; Ustundag, S, 2008)
"Previous studies have shown that the selective aldosterone blocker eplerenone, in doses of up to 200 mg/d, reduces albuminuria in patients with type 2 diabetes."5.12Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. ( Beckerman, B; Epstein, M; Krause, S; Lewin, A; Mukherjee, R; Patni, R; Weinberger, M; Williams, GH, 2006)
"This study compared the efficacy and tolerability of eplerenone and enalapril in 499 patients with stage 1 or 2 hypertension who were randomized to receive eplerenone or enalapril for 6 months in a 3-step titration-to-effect study."5.11Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. ( Burgess, E; Kipnes, MS; Kolloch, RE; Krause, SL; Niegowska, J; Patrick, JL; Roniker, B; Ruilope, LM; Williams, GH, 2004)
"At the doses tested, spironolactone was superior to cilazapril in reducing albuminuria."5.11The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. ( Amit, M; Berla, M; Kedar, Y; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 2004)
"Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure."5.10Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003)
" Spironolactone and eplerenone are the mineralocorticoid receptor (MR) antagonists currently available for the treatment of hypertension."4.82Mineralocorticoid receptor antagonists and hypertension: is there a rationale? ( Gumieniak, O; Williams, GH, 2004)
" Notably, spironolactone treatment concomitantly suppressed the release of Bsg-bearing EVs in correlation with decreased albuminuria."4.31Basigin is released in extracellular vesicles derived from the renal tubular epithelium in response to albuminuria. ( Kadomatsu, K; Kato, N; Kato, S; Kosugi, T; Maeda, K; Maruyama, S; Ryuge, A; Sato, Y; Seko, H; Sugimura, M; Watanabe, T, 2023)
" In our study, we studied if continuous treatment with a mineralocorticoid receptor antagonist, spironolactone (30 mg/kg/day) for 20 days can: 1) attenuate hypertension development and restore inverted 24-h BP rhythm in hypertensive transgenic (mRen-2)27 rats (TGR) measured by telemetry; 2) improve function of the kidneys and heart; 3) be protective against high salt load (1% in water) by mitigating oxidative injury and improving kidney function."4.31Mineralocorticoid receptor blockade protects the kidneys but does not affect inverted blood pressure rhythm in hypertensive transgenic (mRen-2)27 rats. ( Kopkan, L; Majzunova, M; Molcan, L; Sutovska, H; Sykora, M; Zeman, M, 2023)
" We evaluated whether spironolactone reduced albuminuria at the 1-year visit in a subpopulation (N=744)."3.88Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. ( Anand, I; Claggett, B; Desai, AS; Fang, JC; Lewis, EF; O'Meara, E; Pfeffer, MA; Pitt, B; Rouleau, JL; Selvaraj, S; Shah, SJ; Solomon, SD; Sweitzer, NK, 2018)
"Mice receiving eplerenone showed significantly decreased albuminuria and glomerular sclerosis at day 7 and 14 after induction of anti-GBM GN."3.77The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis. ( Eller, K; Huber, JM; Kirsch, AH; Mayer, G; Rosenkranz, AR; Tagwerker, A; Zitt, E, 2011)
" It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension."3.76Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. ( Fukuda, S; Sato, A, 2010)
"A fixed, low-dose of spironolactone, added to chronic ACE inhibitor therapy, reduced blood pressure and urinary albumin excretion in obese subjects with hypertension and preexistent target organ damage."3.75Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. ( Bald, E; Bomback, AS; Chwatko, G; Muskala, P; Nowicki, M, 2009)
" After 1 yr, creatinine clearance and albuminuria declined, and resistance and pulsatility index increased to the same extent in patients with primary aldosteronism treated with either adrenalectomy or spironolactone."3.75Intrarenal hemodynamics in primary aldosteronism before and after treatment. ( Bazzocchi, M; Catena, C; Di Fabio, A; Sechi, LA; Uzzau, A, 2009)
" Patients were randomly divided into 4 groups: low-dose irbesartan (group A), high-dose irbesartan (group B), low-dose irbesartan combined with spironolactone (group C) and high-dose irbesartan combined with spironolactone (group D)."2.87Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. ( Chen, X; Chen, Y; Li, Y; Liu, P; Wang, Y; Zhang, F, 2018)
"Amiloride (5 mg/d) was added to previous triple antihypertensive treatment (including a diuretic and an inhibitor of the renin-angiotensin-aldosterone system) and increased to 10 mg if BP control was not achieved at 4 weeks."2.79Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension. ( Buhl, KB; Gram, J; Hansen, MR; Henriksen, JE; Jacobsen, IA; Jensen, BL; Oxlund, CS; Schousboe, K; Tarnow, L, 2014)
"Primary aldosteronism (PA) has deleterious effects on kidney function independent of blood pressure levels."2.78Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. ( Allolio, B; Beuschlein, F; Diederich, S; Endres, S; Fischer, E; Fourkiotis, V; Lang, K; Quinkler, M; Reincke, M; Rump, LC; Vonend, O; Willenberg, HS, 2013)
"Aldosterone breakthrough has the potential to eliminate the organ-protective effects of RA system inhibitors."2.78Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist. ( Fukuda, S; Sato, A, 2013)
"Twenty Caucasian patients with diabetic nephropathy and nephrotic range albuminuria (>2500 mg/24 h) despite recommended antihypertensive treatment completed this double-masked, randomized crossover trial."2.72Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. ( Boomsma, F; Juhl, TR; Parving, HH; Rossing, K; Rossing, P; Schjoedt, KJ; Tarnow, L, 2006)
"It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape)."2.71Effectiveness of aldosterone blockade in patients with diabetic nephropathy. ( Hayashi, K; Naruse, M; Saruta, T; Sato, A, 2003)
"Diabetic nephropathy is the most common cause of end-stage renal disease in the western world."2.47The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone. ( Schjoedt, KJ, 2011)
"Patients with primary aldosteronism (PA) have a high prevalence of microalbuminuria (MAU), which leads to more severe systemic vascular damage."1.62Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism. ( Hu, J; Li, N; Luo, Q; Wang, G; Wang, M; Wang, X; Zhang, D; Zhang, W, 2021)
"Canrenone is a derivative of spironolactone with lower antiandrogen activity."1.40Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. ( Armanini, D; Bordin, L; Clari, G; Donà, G; Sabbadin, C, 2014)
"Spironolactone treatment did not induce any significant change in blood glucose levels and blood pressure."1.33Role of aldosterone in diabetic nephropathy. ( Cha, DR; Han, JY; Han, KH; Han, SY; Jee, YH; Kang, YS; Kim, HK; Kim, YS, 2005)
"Patients with primary aldosteronism were compared with 100 patients with essential hypertension, matched for severity and duration of hypertension."1.33Long-term renal outcomes in patients with primary aldosteronism. ( Baroselli, S; Catena, C; Colussi, GL; Lapenna, R; Nadalini, E; Novello, M; Sechi, LA, 2006)

Research

Studies (65)

TimeframeStudies, this research(%)All Research%
pre-19902 (3.08)18.7374
1990's0 (0.00)18.2507
2000's24 (36.92)29.6817
2010's33 (50.77)24.3611
2020's6 (9.23)2.80

Authors

AuthorsStudies
Mårup, FH1
Peters, CD1
Christensen, JH1
Birn, H1
Oiwa, A1
Hiwatashi, D1
Takeda, T1
Miyamoto, T1
Kawata, I1
Koinuma, M1
Yamazaki, M1
Komatsu, M1
Sutovska, H1
Molcan, L1
Majzunova, M1
Sykora, M1
Kopkan, L1
Zeman, M1
Watanabe, T1
Maeda, K1
Kato, N1
Seko, H1
Sugimura, M1
Sato, Y1
Ryuge, A1
Kato, S2
Kadomatsu, K1
Maruyama, S2
Kosugi, T1
Mulder, S1
Perco, P1
Oxlund, C3
Mehdi, UF2
Hankemeier, T1
Jacobsen, IA4
Toto, R1
Heerspink, HJL2
Pena, MJ1
Wang, X1
Luo, Q1
Wang, M1
Hu, J1
Zhang, D1
Zhang, W1
Wang, G1
Li, N1
Dojki, FK1
Bakris, G1
Sawai, T1
Dohi, K1
Fujimoto, N1
Okubo, S1
Isaka, N1
Ichikawa, T1
Makino, K1
Okamoto, S1
Koyabu, S1
Kitamura, T1
Ogura, T1
Yamada, T1
Tamaru, S1
Nishikawa, M1
Nakamura, M1
Ito, M1
Chen, Y1
Liu, P1
Chen, X1
Li, Y1
Zhang, F1
Wang, Y1
Rossing, P6
Persson, F4
Selvaraj, S1
Claggett, B1
Shah, SJ1
Anand, I1
Rouleau, JL1
O'Meara, E1
Desai, AS1
Lewis, EF1
Pitt, B1
Sweitzer, NK1
Fang, JC1
Pfeffer, MA1
Solomon, SD1
de Borst, MH1
Laverman, GD1
Navis, G1
Dong, D1
Fan, TT1
Ji, YS1
Yu, JY1
Wu, S1
Zhang, L1
Sato, A3
Fukuda, S2
Mavrakanas, TA1
Gariani, K1
Martin, PY1
Ferreira, JP1
Santos, M1
Almeida, S1
Marques, I1
Bettencourt, P1
Carvalho, H1
Armanini, D1
Sabbadin, C1
Donà, G1
Clari, G1
Bordin, L1
Kawada, N1
Isaka, Y1
Kitamura, H1
Rakugi, H1
Moriyama, T1
Epstein, M2
Ando, K2
Ohtsu, H2
Uchida, S1
Kaname, S1
Arakawa, Y2
Fujita, T2
Oxlund, CS1
Buhl, KB1
Hansen, MR2
Gram, J1
Henriksen, JE1
Schousboe, K1
Tarnow, L2
Jensen, BL2
Makino, H1
Wada, J1
Ogawa, D1
Uzu, T1
Araki, H1
Koya, D1
Kanasaki, K1
Oiso, Y1
Goto, M1
Nishiyama, A1
Kobori, H1
Imai, E1
Ando, M1
Matsuo, S1
Hou, J1
Xiong, W1
Cao, L1
Wen, X1
Li, A1
Lindhardt, M1
Zürbig, P1
Mischak, H1
Kurt, B1
Schwarzensteiner, I1
Stæhr, M1
Svenningsen, P1
Hansen, PB1
Thuesen, AD1
Toft, A1
Hinrichs, GR1
Bistrup, C1
Kang, YS2
Ko, GJ1
Lee, MH1
Song, HK1
Han, SY2
Han, KH2
Kim, HK2
Han, JY2
Cha, DR2
Ustundag, A1
Tugrul, A1
Ustundag, S1
Sut, N1
Demirkan, B1
Davidson, MB1
Wong, A1
Hamrahian, AH1
Stevens, M1
Siraj, ES1
Sechi, LA2
Di Fabio, A1
Bazzocchi, M1
Uzzau, A1
Catena, C2
Whaley-Connell, A1
Habibi, J2
Wei, Y1
Gutweiler, A1
Jellison, J1
Wiedmeyer, CE1
Ferrario, CM2
Sowers, JR2
Jansen, PM1
Danser, AH1
Imholz, BP1
van den Meiracker, AH1
Schjoedt, KJ4
Christensen, PK1
Jorsal, A1
Boomsma, F2
Parving, HH4
Adams-Huet, B1
Raskin, P1
Vega, GL1
Toto, RD1
Bomback, AS1
Muskala, P1
Bald, E1
Chwatko, G1
Nowicki, M1
Derer, W1
Dechend, R1
Müller, DN1
Kubota, K1
Yamaguchi, T1
Nagase, M1
Yamada, A1
Lin, S1
Li, D1
Jia, J1
Zheng, Z1
Jia, Z1
Shang, W1
Liang, W1
Chen, C1
Shi, J1
Ren, Z1
Hu, F1
van Goor, H1
Singhal, PC1
Ding, G1
Irita, J1
Okura, T1
Jotoku, M1
Nagao, T1
Enomoto, D1
Kurata, M1
Desilva, VR1
Miyoshi, K1
Matsui, Y1
Uede, T1
Denhardt, DT1
Rittiling, SR1
Higaki, J1
Zitt, E1
Eller, K1
Huber, JM1
Kirsch, AH1
Tagwerker, A1
Mayer, G1
Rosenkranz, AR1
Whaley-Connell, AT1
Nistala, R1
DeMarco, VG1
Pulakat, L1
Hayden, MR1
Joginpally, T1
Parrish, AR1
Nielsen, SE2
Frandsen, E1
Sugaya, T1
Hess, G1
Zdunek, D1
Shjoedt, KJ1
Suzuki, H1
Shuto, H1
Shuto, C1
Ohara, I1
Inokuma, S1
Abe, Y1
Sukigara, M1
Fourkiotis, V1
Vonend, O1
Diederich, S1
Fischer, E1
Lang, K1
Endres, S1
Beuschlein, F1
Willenberg, HS1
Rump, LC1
Allolio, B1
Reincke, M1
Quinkler, M1
Rossing, K2
Schalkwijk, CG1
Stehouwer, CD1
Tylicki, L1
Lizakowski, S1
Rutkowski, P1
Renke, M1
Sulikowska, B1
Heleniak, Z1
Donderski, R1
Bednarski, R1
Przybylska, M1
Manitius, J1
Rutkowski, B1
Hayashi, K1
Naruse, M1
Saruta, T1
White, WB1
Duprez, D1
St Hillaire, R1
Krause, S2
Roniker, B2
Kuse-Hamilton, J1
Weber, MA1
POLIANTSEVA, LR1
ERMOLENKO, VM1
MAROUDIS, D1
HALKINDAKIS, J1
PSILAKIS, D1
SAKLARIDES, J1
Williams, GH4
Burgess, E1
Kolloch, RE1
Ruilope, LM1
Niegowska, J1
Kipnes, MS1
Patrick, JL1
Krause, SL1
Rachmani, R1
Slavachevsky, I1
Amit, M1
Levi, Z1
Kedar, Y1
Berla, M1
Ravid, M1
Gumieniak, O1
Jee, YH1
Kim, YS1
van de Wal, RM1
Asselbergs, FW1
Plokker, HW1
Smilde, TD1
Lok, D1
van Veldhuisen, DJ1
van Gilst, WH1
Voors, AA1
Simorre, B1
Novello, M1
Lapenna, R1
Baroselli, S1
Nadalini, E1
Colussi, GL1
Juhl, TR1
Guo, C1
Martinez-Vasquez, D1
Mendez, GP1
Toniolo, MF1
Yao, TM1
Oestreicher, EM1
Kikuchi, T1
Lapointe, N1
Pojoga, L1
Ricchiuti, V1
Adler, GK2
Joffe, HV1
Kwong, RY1
Gerhard-Herman, MD1
Rice, C1
Feldman, K1
Weinberger, M1
Lewin, A1
Mukherjee, R1
Patni, R1
Beckerman, B1
Nakhoul, F1
Khankin, E1
Yaccob, A1
Kawachi, H1
Karram, T1
Awaad, H1
Nakhoul, N1
Hoffman, A1
Abassi, Z1
Piecha, G1
Koleganova, N1
Gross, ML1
Geldyyev, A1
Adamczak, M1
Ritz, E1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302]Phase 33,445 participants (Actual)Interventional2006-08-31Completed
Aldosterone and Vascular Disease in Diabetes Mellitus[NCT00214825]46 participants (Actual)Interventional2003-08-31Completed
[NCT01832558]24 participants (Anticipated)Interventional2012-11-30Recruiting
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055]Phase 475 participants (Anticipated)Interventional2023-08-25Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Aborted Cardiac Arrest

First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo0.09
Spironolactone0.05

All-cause Mortality

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo4.6
Spironolactone4.2

Cardiovascular Mortality

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo3.1
Spironolactone2.8

Cardiovascular-related Hospitalization

Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo6.2
Spironolactone5.5

Chloride

Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmEq/L (Least Squares Mean)
Placebo102.33
Spironolactone102.26

Composite Outcome of Cardiovascular Mortality or Cardiovascular-related Hospitalization (i.e., Hospitalization for Myocardial Infarction(MI), Stroke, or the Management of Heart Failure), Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo7.8
Spironolactone7.2

Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo6.6
Spironolactone5.9

Composite Outcome of Sudden Death or Aborted Cardiac Arrest, Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.0

Composite Outcome of Sudden Death, Aborted Cardiac Arrest, or Hospitalization for the Management of Ventricular Tachycardia, Whichever Occurred First

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.0

Depression Symptoms, as Measured by Patient Health Questionnaire.

"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo5.6
Spironolactone5.1

Deterioration of Renal Function

First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo2.2
Spironolactone3.2

Development of Atrial Fibrillation, Among Subjects Without a History of Atrial Fibrillation at Baseline.

First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.4
Spironolactone1.4

Estimated Glomerular Filtration Rate (GFR)

Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmL/min/1.73m2 (Least Squares Mean)
Placebo67.50
Spironolactone65.20

Hospitalization for Any Reason

First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo20.0
Spironolactone18.8

Hospitalization for the Management of Heart Failure

First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo4.6
Spironolactone3.8

Myocardial Infarction

First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.2

New Onset Diabetes Mellitus, Among Subjects Without a History of Diabetes Mellitus at Baseline.

First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo0.7
Spironolactone0.7

Potassium

Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmEq/L (Least Squares Mean)
Placebo4.32
Spironolactone4.49

Quality of Life, as Measured by McMaster Overall Treatment Evaluation Questionnaire.

"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo1.2
Spironolactone1.2

Quality of Life, as Measured by the EuroQOL Visual Analog Scale.

"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo65.9
Spironolactone66.4

Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire.

"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionunits on a scale (Least Squares Mean)
Placebo63.1
Spironolactone64.4

Serum Creatinine

Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Interventionmg/dL (Least Squares Mean)
Placebo1.11
Spironolactone1.17

Sodium

Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionmEq/L (Least Squares Mean)
Placebo140.95
Spironolactone140.33

Stroke

First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo1.1
Spironolactone1.0

Total Hospitalizations (Including Repeat Hospitalizations) for the Management of Heart Failure

(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

InterventionEvents per 100 person-years (Number)
Placebo8.3
Spironolactone6.8

Reviews

7 reviews available for spironolactone and Albuminuria

ArticleYear
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
    Current opinion in nephrology and hypertension, 2017, Volume: 26, Issue:5

    Topics: Albuminuria; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eplerenone

2017
Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    European journal of internal medicine, 2014, Volume: 25, Issue:2

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetic Ne

2014
Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
    Clinical therapeutics, 2015, Volume: 37, Issue:9

    Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Creatinine; Diabetic Nephropathies; Disease Pr

2015
Aldosterone-receptor antagonism in hypertension.
    Journal of hypertension, 2009, Volume: 27, Issue:4

    Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; D

2009
[Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
    MMW Fortschritte der Medizin, 2010, Feb-11, Volume: 152, Issue:6

    Topics: Albuminuria; Diabetes Mellitus, Type 2; Eplerenone; Female; Heart Failure; Humans; Hyperaldosteronis

2010
The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
    Danish medical bulletin, 2011, Volume: 58, Issue:4

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cyto

2011
Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
    Current hypertension reports, 2004, Volume: 6, Issue:4

    Topics: Albuminuria; Aldosterone; Animals; Drug Therapy, Combination; Eplerenone; Humans; Hyperkalemia; Hype

2004

Trials

29 trials available for spironolactone and Albuminuria

ArticleYear
Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled
    BMJ open, 2022, Feb-21, Volume: 12, Issue:2

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Hum

2022
Efficacy and Safety of Low-dose Spironolactone for Chronic Kidney Disease in Type 2 Diabetes.
    The Journal of clinical endocrinology and metabolism, 2023, 08-18, Volume: 108, Issue:9

    Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Humans; Hyperkalemia; Mineralocorticoid Receptor Anta

2023
Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.
    Translational research : the journal of laboratory and clinical medicine, 2020, Volume: 222

    Topics: Albumins; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans

2020
Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension.
    Journal of clinical hypertension (Greenwich, Conn.), 2017, Volume: 19, Issue:10

    Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blo

2017
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
    The American journal of the medical sciences, 2018, Volume: 355, Issue:5

    Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph

2018
Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:10

    Topics: Aged; Albuminuria; Aldosterone; Amides; Blood Pressure; Dose-Response Relationship, Drug; Drug Thera

2013
The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial.
    Nephrology (Carlton, Vic.), 2014, Volume: 19, Issue:3

    Topics: Aged; Aged, 80 and over; Albuminuria; Biomarkers; Female; Heart Failure; Humans; Male; Prospective S

2014
A pilot study of the effects of eplerenone add-on therapy in patients taking renin-angiotensin system blockers.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2015, Volume: 16, Issue:2

    Topics: Adult; Aged; Albuminuria; Aldosterone; Blood Pressure; Diastole; Eplerenone; Female; Glomerular Filt

2015
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:12

    Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Creatinine; Double-Blind Method; Eplerenone; Fema

2014
Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
    Journal of the American Society of Hypertension : JASH, 2014, Volume: 8, Issue:12

    Topics: Adult; Aged; Albuminuria; Amiloride; Antihypertensive Agents; Blotting, Western; Creatinine; Diabete

2014
Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Clinical and experimental nephrology, 2015, Volume: 19, Issue:6

    Topics: Adult; Aged; Albuminuria; Aldosterone; Asian People; Blood Pressure; Diabetes Mellitus, Type 2; Diab

2015
Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018, 02-01, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans

2018
Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin.
    Pflugers Archiv : European journal of physiology, 2017, Volume: 469, Issue:5-6

    Topics: Adult; Aged; Albuminuria; Aldosterone; Animals; Antihypertensive Agents; Diabetic Nephropathies; Fem

2017
The effects of spironolactone on nephron function in patients with diabetic nephropathy.
    Renal failure, 2008, Volume: 30, Issue:10

    Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh

2008
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2008, Volume: 14, Issue:8

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy

2008
Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:11

    Topics: Adult; Aged; Albuminuria; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blin

2009
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:12

    Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor

2009
Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effect
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:6

    Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh

2010
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Diabetic medicine : a journal of the British Diabetic Association, 2012, Volume: 29, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Angiotens

2012
Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.
    European journal of endocrinology, 2013, Volume: 168, Issue:1

    Topics: Adrenalectomy; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Creatinine; Eplerenone;

2013
Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2013, Volume: 14, Issue:2

    Topics: Albuminuria; Biomarkers; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; End

2013
The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?.
    Kidney & blood pressure research, 2012, Volume: 36, Issue:1

    Topics: Adult; Albuminuria; Amides; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Comorbidity

2012
Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:1

    Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diab

2003
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:5

    Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channe

2003
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
    The American journal of cardiology, 2004, Apr-15, Volume: 93, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Blood Pressure; Cough; Drug To

2004
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.
    Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:5

    Topics: Aged; Albuminuria; Blood Pressure; Cilazapril; Creatinine; Diabetic Nephropathies; Drug Therapy, Com

2004
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
    Kidney international, 2006, Volume: 70, Issue:3

    Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitor

2006
Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
    The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:7

    Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Brachia

2007
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Clinical journal of the American Society of Nephrology : CJASN, 2006, Volume: 1, Issue:5

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diabetes Me

2006
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Clinical journal of the American Society of Nephrology : CJASN, 2006, Volume: 1, Issue:5

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diabetes Me

2006
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Clinical journal of the American Society of Nephrology : CJASN, 2006, Volume: 1, Issue:5

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diabetes Me

2006
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Clinical journal of the American Society of Nephrology : CJASN, 2006, Volume: 1, Issue:5

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Creatinine; Diabetes Me

2006

Other Studies

29 other studies available for spironolactone and Albuminuria

ArticleYear
Mineralocorticoid receptor blockade protects the kidneys but does not affect inverted blood pressure rhythm in hypertensive transgenic (mRen-2)27 rats.
    Molecular and cellular endocrinology, 2023, 07-15, Volume: 572

    Topics: Albuminuria; Aldosterone; Animals; Animals, Genetically Modified; Blood Pressure; Hypertension; Kidn

2023
Basigin is released in extracellular vesicles derived from the renal tubular epithelium in response to albuminuria.
    Nephrology (Carlton, Vic.), 2023, Volume: 28, Issue:11

    Topics: Adult; Albuminuria; Basigin; Epithelium; Extracellular Vesicles; Humans; Proteinuria; Renal Insuffic

2023
Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2021, Volume: 44, Issue:4

    Topics: Albuminuria; Humans; Hyperaldosteronism; Medication Adherence; Spironolactone; Treatment Outcome

2021
Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria-A Path for Improved Renoprotection?
    The American journal of the medical sciences, 2018, Volume: 355, Issue:5

    Topics: Albuminuria; Drug Therapy, Combination; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Rece

2018
Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Circulation. Heart failure, 2018, Volume: 11, Issue:11

    Topics: Aged; Aged, 80 and over; Albuminuria; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged;

2018
Escaping residual albuminuria in hypertension: should we start eplerenone or reduce salt intake?
    Hypertension research : official journal of the Japanese Society of Hypertension, 2019, Volume: 42, Issue:4

    Topics: Albuminuria; Diabetes Mellitus; Eplerenone; Humans; Hypertension; Receptors, Mineralocorticoid; Sodi

2019
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.
    International urology and nephrology, 2019, Volume: 51, Issue:4

    Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme 2; Animals; Autophagy; Beclin-1; Diabetes Me

2019
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:7

    Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenone; Humans; Hypertension;

2014
Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease.
    The lancet. Diabetes & endocrinology, 2014, Volume: 2, Issue:12

    Topics: Albuminuria; Female; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Protective

2014
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:1

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Collagen Type IV; Dia

2009
Intrarenal hemodynamics in primary aldosteronism before and after treatment.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:4

    Topics: Adrenalectomy; Adult; Aged; Albuminuria; Blood Pressure; Female; Heart Rate; Hemodynamics; Humans; H

2009
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat.
    American journal of physiology. Renal physiology, 2009, Volume: 296, Issue:5

    Topics: Albuminuria; Animals; Blood Pressure; Dose-Response Relationship, Drug; Glomerular Filtration Rate;

2009
Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension.
    Journal of human hypertension, 2010, Volume: 24, Issue:6

    Topics: Aged; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; A

2010
Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Clinical nephrology, 2009, Volume: 72, Issue:6

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitoring, Am

2009
Spironolactone ameliorates podocytic adhesive capacity via restoring integrin alpha 3 expression in streptozotocin-induced diabetic rats.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2010, Volume: 11, Issue:3

    Topics: Albuminuria; Animals; Cell Adhesion; Diabetes Mellitus, Experimental; Integrin alpha3beta1; Male; Po

2010
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:3

    Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis;

2011
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
    American journal of physiology. Renal physiology, 2011, Volume: 301, Issue:4

    Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male;

2011
The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis.
    International journal of clinical and experimental pathology, 2011, Aug-15, Volume: 4, Issue:6

    Topics: Albuminuria; Animals; Anti-Glomerular Basement Membrane Disease; CD4-Positive T-Lymphocytes; CD8-Pos

2011
Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway.
    American journal of nephrology, 2012, Volume: 35, Issue:1

    Topics: Albuminuria; Animals; Animals, Genetically Modified; Blood Pressure; Immunohistochemistry; Kidney Tu

2012
Eplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndrome.
    Therapeutic advances in cardiovascular disease, 2012, Volume: 6, Issue:4

    Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Eplerenone; Female; Humans; Male; Metabo

2012
[ALDOSTERONE AND SPIROLACTONES IN THE CLINICAL TREATMENT OF INTERNAL DISEASES (REVIEW OF THE LITERATURE AND ANALYSIS OF PERSONAL CASES)].
    Sovetskaia meditsina, 1963, Volume: 27

    Topics: Albuminuria; Aldosterone; Blood; Cardiovascular Diseases; Drug Therapy; Humans; Hyperaldosteronism;

1963
THE EFFECT OF 17-SPIRONOLACTONES IN TOXEMIA.
    The Journal of the International College of Surgeons, 1964, Volume: 42

    Topics: Albuminuria; Blood Chemical Analysis; Blood Pressure; Blood Pressure Determination; Drug Therapy; Ed

1964
Role of aldosterone in diabetic nephropathy.
    Nephrology (Carlton, Vic.), 2005, Volume: 10 Suppl

    Topics: Albuminuria; Aldosterone; Animals; Cells, Cultured; Chemokine CCL2; Collagen; Connective Tissue Grow

2005
High prevalence of microalbuminuria in chronic heart failure patients.
    Journal of cardiac failure, 2005, Volume: 11, Issue:8

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Angiotensin-Converti

2005
[41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece].
    La Revue de medecine interne, 2006, Volume: 27, Issue:4

    Topics: Aged; Albuminuria; Antihypertensive Agents; Bone Density Conservation Agents; Cardiovascular Disease

2006
Long-term renal outcomes in patients with primary aldosteronism.
    JAMA, 2006, Jun-14, Volume: 295, Issue:22

    Topics: Adrenalectomy; Adult; Albuminuria; Female; Glomerular Filtration Rate; Humans; Hyperaldosteronism; H

2006
Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
    Endocrinology, 2006, Volume: 147, Issue:11

    Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus,

2006
Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    American journal of physiology. Renal physiology, 2008, Volume: 294, Issue:3

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Blood Urea Nitrogen;

2008
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination.
    American journal of physiology. Renal physiology, 2008, Volume: 295, Issue:1

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Collagen Type IV; Desmin; Dihydralazi

2008